Condition
Adult Primary Liver Cancer
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03680508Phase 2Active Not RecruitingPrimary
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
NCT04390724Recruiting
Optimizing Y90 Therapy for Radiation Lobectomy
NCT00513461Phase 2CompletedPrimary
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
NCT01908166Not ApplicableCompletedPrimary
Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions
Showing all 4 trials